Ignite Creation Date:
2025-12-24 @ 11:19 PM
Ignite Modification Date:
2026-01-01 @ 5:07 PM
Study NCT ID:
NCT07038356
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2025-05-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C570240', 'term': 'empagliflozin'}, {'id': 'D013607', 'term': 'Tablets'}], 'ancestors': [{'id': 'D004304', 'term': 'Dosage Forms'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 536}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2025-12-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-09', 'completionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-09', 'studyFirstSubmitDate': '2025-05-23', 'studyFirstSubmitQcDate': '2025-06-17', 'lastUpdatePostDateStruct': {'date': '2025-12-17', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-06-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-04-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Four-step hierarchical composite primary endpoint; win ratio based on the following parameters (day 90): time to all-cause death, number of heart failure events per patient, time to first heart failure event, eGFR decrease from baseline to day 90', 'timeFrame': 'day 90', 'description': 'The study uses a four-step hierarchical composite primary endpoint (win ratio):\n\n1. time to all-cause death, days (day 90)\n2. number of heart failure events per patient (day 90)\n3. time to first heart failure event, days (day 90)\n4. eGFR decrease from baseline to day 90 (with a between-patient threshold defined as ≥5 ml/min/1.73 m²)'}], 'secondaryOutcomes': [{'measure': 'Cardiovascular and total mortality on day 90', 'timeFrame': 'day 90'}, {'measure': 'Number of patients alive and without re-hospitalization on day 90', 'timeFrame': 'day 90'}, {'measure': 'Re-hospitalization after initial discharge, including reason: time to first rehospitalization after discharge', 'timeFrame': 'day 90'}, {'measure': 'Re-hospitalization after initial discharge, including reason: numbers of re-hospitalizations', 'timeFrame': 'day 90'}, {'measure': 'Number of patients with a decrease in eGFR of 5 ml/min/1.73 m² or more from baseline to day 90', 'timeFrame': 'day 90'}, {'measure': 'Daily and cumulative urine output (UOP, ml) measured from day 1 until day 6', 'timeFrame': 'day 1 until day 6'}, {'measure': 'Diuretic efficiency (ml urine per mg furosemide equivalent) from day 1 to day 6', 'timeFrame': 'day 1 until day 6'}, {'measure': 'Change in body weight from baseline to day 1, day 3, day 6, discharge (supposed between day 6-10), day 30, and day 90', 'timeFrame': 'day 1, day 3, day 6, discharge (supposed between day 6-10), day 30, and day 90'}, {'measure': 'Renal function at baseline, day 3, day 6, day 30, and day 90', 'timeFrame': 'baseline, day 3, day 6, day 30, and day 90', 'description': '* Decrease in eGFR of \\>20 ml/min/1.73 m2\n* Doubling of serum creatinine\n* Need for renal replacement therapy\n* Total urinary sodium excretion and fractional excretion of sodium'}, {'measure': 'Liver function: bilirubin (nmol/ml) at baseline, day 3, day 6, day 30, and day 90', 'timeFrame': 'baseline, day 3, day 6, day 30, and day 90'}, {'measure': 'Liver function: serum aminotransferases (µmol/l*s) at baseline, day 3, day 6, day 30, and day 90', 'timeFrame': 'baseline, day 3, day 6, day 30, and day 90'}, {'measure': 'Liver function: relevant change in coagulation status (Quick/INR, %, 3X upper limit of normal) at baseline, day 3, day 6, day 30, and day 90', 'timeFrame': 'baseline, day 3, day 6, day 30, and day 90'}, {'measure': 'Change in NT-proBNP (N-terminal pro Brain natriuretic peptide, pg/ml) (alternatively calculated from BNP, Brain natriuretic peptide, pg/ml) from baseline to day 6, day 30, and day 90', 'timeFrame': 'baseline to day 6, day 30, and day 90'}, {'measure': 'Quality of life (EQ-5D-3L questionnaire, 3-level version of the EuroQol five dimensional descriptive system ) on day 0, at hospital discharge (supposed between day 6-10), and on day 30', 'timeFrame': 'day 0, at hospital discharge (supposed between day 6-10), and on day 30', 'description': 'Quality of life: EQ-5D-3L questionaire. The EQ-5D-3L questionnaire consists of two parts: part one contains questions about patients mobility, self-care, usual activities, pain/discomfort, anxiety/depression, with scores from 1 (no problem), 2 (some problems), and 3 (extreme problems). Part two measures patients health on a scale from 0 (the worst imaginable health) to 100 (the best imaginable health), on day 0, at hospital discharge (supposed between day 6-10), and on day 30'}, {'measure': 'Severity of heart failure (HF): KCCQ-12 questionnaire (Kansas City Cardiomyopathy Questionnaire comprising 12 items) on day 0, at hospital discharge (supposed between day 6-10), and on day 30', 'timeFrame': 'day 0, at hospital discharge (supposed between day 6-10), and on day 30', 'description': 'KCCQ-12 questionnaire: scores range from 0 to 100, with higher scores indicating better health status, on day 0, at hospital discharge (supposed between day 6-10), and on day 30'}, {'measure': 'Intermediate Care Unit (IMC) / Intensive Care Unit (ICU) and hospital length of stay, days until discharge (supposed between day 6-10)', 'timeFrame': 'discharge (supposed between day 6-10)'}, {'measure': 'Single parameters of primary endpoint: time to all-cause death (day 90)', 'timeFrame': 'day 90'}, {'measure': 'Single parameters of primary endpoint: number of heart failure events per patient (day 90)', 'timeFrame': 'day 90'}, {'measure': 'Single parameters of primary endpoint: time to first heart failure event (day 90)', 'timeFrame': 'day 90'}, {'measure': 'Single parameters of primary endpoint: eGFR decrease from baseline to day 90 (ml/min/1.73 m²)', 'timeFrame': 'day 90'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Acute Decompensated Heart Failure (ADHF)']}, 'descriptionModule': {'briefSummary': 'The goal of this clinical trial is to test the hypothesis that the continuation of empagliflozin during decongestive therapy in the setting of acute decompensated and hospitalized heart failure patients is not inferior compared to therapy cessation during the acute heart failure hospitalization.\n\nRandomized treatment (plus standard medical care) in patients with acute decompensated heart failure is one (1) tablet daily of empagliflozin 10 mg or matching placebo during the in-hospital stay (up to a maximum of 30 days), followed by treatment with empagliflozin 10 mg daily after discharge (but no later than day 31) until day 90.\n\nThe primary outcome measure is the combined hierarchical endpoint of all-cause mortality, heart failure hospitalization and worsening renal function at 90 days after admission.\n\nSecondary outcome measures are the effects on urine output, diuretic efficiency, quality-of-life and the need for further administration of diuretics.\n\nParticipants will\n\n* Take one tablet of study medication once daily (day 1 to day 90)\n* Restrict fluid intake to 1.5 liters of fluid per day and record the daily fluid intake for the study from day 1 to day 6 in the patient diary\n* Measure the urine output (day 1 to day 6)\n* Fill in Questionnaires (EQ-5D-3L (3-level version of the EuroQol five dimensional descriptive system), KCCQ-12 (Kansas City Cardiomyopathy Questionnaire comprising 12 items)) on day 0 (Baseline), at hospital discharge, and on day 30'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients (age ≥ 18 years) with acute decompensated heart failure (HF) according to clinical assessment on active therapy with a SGLT2 inhibitor\n* Brain Natriuretic Peptide (BNP) \\>100 pg/ml or N-terminal pro-BNP (NTproBNP) \\>300 pg/ml\n* Written informed consent obtained\n* Women of childbearing potential: negative pregnancy test and use of a highly effective method of contraception\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Chronic Kidney Disease (CKD) with eGFR\\<20 ml/min, or end-stage renal failure with the need for chronic dialysis treatment\n* Acute kidney injury (AKI) requiring dialysis treatment\n* Known intolerance to empagliflozin\n* Acute heart failure without signs of congestion ("dry" patient)\n* Indication for coronary angiography or any foreseeable administration of a contrast media\n* Need for hemofiltration or any other form of extracorporeal therapy\n* Planned surgery\n* Previous participation in this trial or recent participation in another clinical trial (within the last 4 weeks before inclusion)\n* Identification of any causes of heart failure leading to decompensation that needs urgent management (like acute coronary syndrome, severe unstable arrhythmias, mechanical causes, acute pulmonary embolism)\n* Incapacity to understand and / or to provide written informed consent\n* Obvious uncontrolled substance abuse\n* Pregnancy, breastfeeding'}, 'identificationModule': {'nctId': 'NCT07038356', 'acronym': 'EMPA-CON', 'briefTitle': 'Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure', 'organization': {'class': 'OTHER', 'fullName': 'Jena University Hospital'}, 'officialTitle': 'Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure', 'orgStudyIdInfo': {'id': 'EMPA-CON_ZKSJ0162'}, 'secondaryIdInfos': [{'id': '2024-517977-26-00', 'type': 'CTIS'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'control', 'description': 'Randomized treatment with placebo (one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90.', 'interventionNames': ['Drug: Placebo']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'intervention', 'description': 'Drug: Empagliflozin (10 mg/day), film-coated tablet Randomized treatment with 10 mg empagliflozin (Jardiance, one tablet) or placebo daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90', 'interventionNames': ['Drug: Empagliflozin 10 MG Oral Tablet [Jardiance]']}], 'interventions': [{'name': 'Empagliflozin 10 MG Oral Tablet [Jardiance]', 'type': 'DRUG', 'description': 'Randomized treatment with 10 mg empagliflozin (Jardiance, one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90', 'armGroupLabels': ['intervention']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Randomized treatment with placebo (one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90', 'armGroupLabels': ['control']}]}, 'contactsLocationsModule': {'locations': [{'zip': '07747', 'city': 'Jena', 'state': 'Thuringia', 'status': 'RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Julian Westphal, Dr.', 'role': 'CONTACT', 'email': 'Julian.Westphal@med.uni-jena.de', 'phone': '036419324199'}], 'facility': 'Jena University Hospital', 'geoPoint': {'lat': 50.92878, 'lon': 11.5899}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Christian Schulze', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Director of Department of Internal Medicine I at Jena University Hospital and Professor of Medicine at Friedrich Schiller University Jena', 'investigatorFullName': 'Christian Schulze', 'investigatorAffiliation': 'Jena University Hospital'}}}}